What will the FDA's decision be on Venglustat by Sanofi in 2026?

If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Venglustat is an oral small-molecule drug developed by Sanofi that works by slowing down the body's production of a fatty substance called glucosylceramide, which builds up to harmful levels in people with Gaucher disease — think of it like adjusting a factory's output dial rather than cleaning up the mess after the fact. It belongs to a class called substrate reduction therapy (SRT), meaning it targets the upstream source of the problem rather than replacing a missing enzyme. Because it is a small molecule taken by mouth and designed to cross into the brain, it has potential to address the neurological symptoms that older enzyme-based treatments cannot reach.